nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—CYP2C9—Estropipate—osteoporosis	0.111	0.195	CbGbCtD
Glipizide—CYP3A4—Estropipate—osteoporosis	0.0646	0.113	CbGbCtD
Glipizide—CYP3A4—Calcitriol—osteoporosis	0.0646	0.113	CbGbCtD
Glipizide—CYP2C9—Cholecalciferol—osteoporosis	0.0573	0.1	CbGbCtD
Glipizide—CYP3A4—Ergocalciferol—osteoporosis	0.0517	0.0905	CbGbCtD
Glipizide—CYP2C9—Estradiol—osteoporosis	0.0462	0.0808	CbGbCtD
Glipizide—CYP3A4—Raloxifene—osteoporosis	0.0431	0.0755	CbGbCtD
Glipizide—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0417	0.0729	CbGbCtD
Glipizide—CYP3A4—Cholecalciferol—osteoporosis	0.0333	0.0583	CbGbCtD
Glipizide—CYP3A4—Conjugated Estrogens—osteoporosis	0.0306	0.0535	CbGbCtD
Glipizide—CYP3A4—Estradiol—osteoporosis	0.0268	0.047	CbGbCtD
Glipizide—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00244	0.0392	CbGpPWpGaD
Glipizide—PPARG—SREBP signalling—FDPS—osteoporosis	0.00198	0.0319	CbGpPWpGaD
Glipizide—PPARG—Differentiation of white and brown adipocyte   —BMP2—osteoporosis	0.00176	0.0283	CbGpPWpGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—LRP5—osteoporosis	0.00175	0.028	CbGpPWpGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—LRP6—osteoporosis	0.00167	0.0268	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—ID4—osteoporosis	0.00139	0.0224	CbGpPWpGaD
Glipizide—KCNJ11—Type II diabetes mellitus—IRS1—osteoporosis	0.00126	0.0203	CbGpPWpGaD
Glipizide—ABCC8—Regulation of insulin secretion—RAP1A—osteoporosis	0.00118	0.019	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—NFATC1—osteoporosis	0.00117	0.0188	CbGpPWpGaD
Glipizide—KCNJ11—Regulation of insulin secretion—RAP1A—osteoporosis	0.00115	0.0184	CbGpPWpGaD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00114	0.0184	CbGpPWpGaD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—IRS2—osteoporosis	0.00107	0.0172	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors—ESR2—osteoporosis	0.00106	0.0171	CbGpPWpGaD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—LEP—osteoporosis	0.00105	0.0168	CbGpPWpGaD
Glipizide—PPARG—Differentiation of white and brown adipocyte   —LEP—osteoporosis	0.000944	0.0152	CbGpPWpGaD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—IRS1—osteoporosis	0.000933	0.015	CbGpPWpGaD
Glipizide—ABCC8—Integration of energy metabolism—RAP1A—osteoporosis	0.000931	0.015	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000922	0.0148	CbGpPWpGaD
Glipizide—KCNJ11—Integration of energy metabolism—RAP1A—osteoporosis	0.000903	0.0145	CbGpPWpGaD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—GPD2—osteoporosis	0.000874	0.014	CbGpPWpGaD
Glipizide—PPARG—Regulation of retinoblastoma protein—BGLAP—osteoporosis	0.000854	0.0137	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors—VDR—osteoporosis	0.000844	0.0135	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00084	0.0135	CbGpPWpGaD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—WNT1—osteoporosis	0.000791	0.0127	CbGpPWpGaD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—OXCT1—osteoporosis	0.000679	0.0109	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.000667	0.0107	CbGpPWpGaD
Glipizide—KCNJ11—Type II diabetes mellitus—TNF—osteoporosis	0.000654	0.0105	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors—ESR1—osteoporosis	0.000645	0.0104	CbGpPWpGaD
Glipizide—ABCC8—Regulation of insulin secretion—ADCY5—osteoporosis	0.000625	0.01	CbGpPWpGaD
Glipizide—KCNJ11—Regulation of insulin secretion—ADCY5—osteoporosis	0.000606	0.00974	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—WNT1—osteoporosis	0.00052	0.00836	CbGpPWpGaD
Glipizide—Discomfort—Pamidronate—osteoporosis	0.000515	0.00141	CcSEcCtD
Glipizide—Gastrointestinal pain—Calcitriol—osteoporosis	0.000511	0.00139	CcSEcCtD
Glipizide—Abdominal pain—Raloxifene—osteoporosis	0.000509	0.00139	CcSEcCtD
Glipizide—PPARG—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.000509	0.00818	CbGpPWpGaD
Glipizide—Vision blurred—Conjugated Estrogens—osteoporosis	0.000508	0.00138	CcSEcCtD
Glipizide—Urticaria—Ibandronate—osteoporosis	0.000507	0.00138	CcSEcCtD
Glipizide—Malaise—Zoledronate—osteoporosis	0.000504	0.00138	CcSEcCtD
Glipizide—Abdominal pain—Ibandronate—osteoporosis	0.000504	0.00138	CcSEcCtD
Glipizide—Confusional state—Pamidronate—osteoporosis	0.000504	0.00137	CcSEcCtD
Glipizide—Vertigo—Zoledronate—osteoporosis	0.000503	0.00137	CcSEcCtD
Glipizide—Syncope—Zoledronate—osteoporosis	0.000502	0.00137	CcSEcCtD
Glipizide—Leukopenia—Zoledronate—osteoporosis	0.000501	0.00137	CcSEcCtD
Glipizide—Oedema—Pamidronate—osteoporosis	0.0005	0.00136	CcSEcCtD
Glipizide—Rhinitis—Estradiol—osteoporosis	0.000496	0.00135	CcSEcCtD
Glipizide—Urticaria—Calcitriol—osteoporosis	0.000496	0.00135	CcSEcCtD
Glipizide—Hepatitis—Estradiol—osteoporosis	0.000495	0.00135	CcSEcCtD
Glipizide—Abdominal pain—Calcitriol—osteoporosis	0.000494	0.00135	CcSEcCtD
Glipizide—Hypoaesthesia—Estradiol—osteoporosis	0.000493	0.00134	CcSEcCtD
Glipizide—Shock—Pamidronate—osteoporosis	0.000492	0.00134	CcSEcCtD
Glipizide—ABCC8—Integration of energy metabolism—ADCY5—osteoporosis	0.000492	0.0079	CbGpPWpGaD
Glipizide—Loss of consciousness—Zoledronate—osteoporosis	0.000492	0.00134	CcSEcCtD
Glipizide—Pharyngitis—Estradiol—osteoporosis	0.000491	0.00134	CcSEcCtD
Glipizide—Hypersensitivity—Estropipate—osteoporosis	0.00049	0.00134	CcSEcCtD
Glipizide—Thrombocytopenia—Pamidronate—osteoporosis	0.000489	0.00133	CcSEcCtD
Glipizide—Vomiting—Etidronic acid—osteoporosis	0.000489	0.00133	CcSEcCtD
Glipizide—Rash—Etidronic acid—osteoporosis	0.000485	0.00132	CcSEcCtD
Glipizide—Dermatitis—Etidronic acid—osteoporosis	0.000484	0.00132	CcSEcCtD
Glipizide—Vertigo—Conjugated Estrogens—osteoporosis	0.000484	0.00132	CcSEcCtD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—TNF—osteoporosis	0.000484	0.00777	CbGpPWpGaD
Glipizide—Hyperhidrosis—Pamidronate—osteoporosis	0.000483	0.00132	CcSEcCtD
Glipizide—Syncope—Conjugated Estrogens—osteoporosis	0.000483	0.00132	CcSEcCtD
Glipizide—Hypertension—Zoledronate—osteoporosis	0.000483	0.00132	CcSEcCtD
Glipizide—Hypersensitivity—Alendronate—osteoporosis	0.000483	0.00132	CcSEcCtD
Glipizide—Headache—Etidronic acid—osteoporosis	0.000482	0.00131	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000479	0.00131	CcSEcCtD
Glipizide—Asthenia—Estropipate—osteoporosis	0.000477	0.0013	CcSEcCtD
Glipizide—Visual impairment—Estradiol—osteoporosis	0.000477	0.0013	CcSEcCtD
Glipizide—KCNJ11—Integration of energy metabolism—ADCY5—osteoporosis	0.000477	0.00766	CbGpPWpGaD
Glipizide—Anorexia—Pamidronate—osteoporosis	0.000476	0.0013	CcSEcCtD
Glipizide—Myalgia—Zoledronate—osteoporosis	0.000476	0.0013	CcSEcCtD
Glipizide—Arthralgia—Zoledronate—osteoporosis	0.000476	0.0013	CcSEcCtD
Glipizide—Insomnia—Risedronate—osteoporosis	0.000476	0.0013	CcSEcCtD
Glipizide—Anxiety—Zoledronate—osteoporosis	0.000475	0.00129	CcSEcCtD
Glipizide—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000473	0.00129	CcSEcCtD
Glipizide—Paraesthesia—Risedronate—osteoporosis	0.000472	0.00129	CcSEcCtD
Glipizide—PPARG—Adipogenesis—BMP2—osteoporosis	0.000471	0.00756	CbGpPWpGaD
Glipizide—Pruritus—Estropipate—osteoporosis	0.000471	0.00128	CcSEcCtD
Glipizide—Discomfort—Zoledronate—osteoporosis	0.000471	0.00128	CcSEcCtD
Glipizide—Asthenia—Alendronate—osteoporosis	0.00047	0.00128	CcSEcCtD
Glipizide—Hypersensitivity—Ibandronate—osteoporosis	0.00047	0.00128	CcSEcCtD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000469	0.00754	CbGpPWpGaD
Glipizide—Dyspnoea—Risedronate—osteoporosis	0.000469	0.00128	CcSEcCtD
Glipizide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000466	0.00127	CcSEcCtD
Glipizide—Pruritus—Alendronate—osteoporosis	0.000464	0.00126	CcSEcCtD
Glipizide—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000463	0.00744	CbGpPWpGaD
Glipizide—Dyspepsia—Risedronate—osteoporosis	0.000463	0.00126	CcSEcCtD
Glipizide—Eye disorder—Estradiol—osteoporosis	0.000463	0.00126	CcSEcCtD
Glipizide—Constipation—Ethinyl Estradiol—osteoporosis	0.000461	0.00126	CcSEcCtD
Glipizide—Confusional state—Zoledronate—osteoporosis	0.00046	0.00126	CcSEcCtD
Glipizide—Hypersensitivity—Calcitriol—osteoporosis	0.00046	0.00126	CcSEcCtD
Glipizide—Flushing—Estradiol—osteoporosis	0.00046	0.00125	CcSEcCtD
Glipizide—Myalgia—Conjugated Estrogens—osteoporosis	0.000459	0.00125	CcSEcCtD
Glipizide—Arthralgia—Conjugated Estrogens—osteoporosis	0.000459	0.00125	CcSEcCtD
Glipizide—Asthenia—Ibandronate—osteoporosis	0.000458	0.00125	CcSEcCtD
Glipizide—Anxiety—Conjugated Estrogens—osteoporosis	0.000457	0.00125	CcSEcCtD
Glipizide—Nausea—Etidronic acid—osteoporosis	0.000457	0.00125	CcSEcCtD
Glipizide—Oedema—Zoledronate—osteoporosis	0.000457	0.00125	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000455	0.00124	CcSEcCtD
Glipizide—Diarrhoea—Estropipate—osteoporosis	0.000455	0.00124	CcSEcCtD
Glipizide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000454	0.00124	CcSEcCtD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.000453	0.00728	CbGpPWpGaD
Glipizide—Insomnia—Pamidronate—osteoporosis	0.000452	0.00123	CcSEcCtD
Glipizide—Pruritus—Ibandronate—osteoporosis	0.000451	0.00123	CcSEcCtD
Glipizide—Pain—Risedronate—osteoporosis	0.00045	0.00123	CcSEcCtD
Glipizide—Constipation—Risedronate—osteoporosis	0.00045	0.00123	CcSEcCtD
Glipizide—Shock—Zoledronate—osteoporosis	0.000449	0.00123	CcSEcCtD
Glipizide—Paraesthesia—Pamidronate—osteoporosis	0.000449	0.00122	CcSEcCtD
Glipizide—Diarrhoea—Alendronate—osteoporosis	0.000448	0.00122	CcSEcCtD
Glipizide—Asthenia—Calcitriol—osteoporosis	0.000448	0.00122	CcSEcCtD
Glipizide—Thrombocytopenia—Zoledronate—osteoporosis	0.000447	0.00122	CcSEcCtD
Glipizide—Dyspnoea—Pamidronate—osteoporosis	0.000446	0.00122	CcSEcCtD
Glipizide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000444	0.00121	CcSEcCtD
Glipizide—Chills—Estradiol—osteoporosis	0.000444	0.00121	CcSEcCtD
Glipizide—Somnolence—Pamidronate—osteoporosis	0.000444	0.00121	CcSEcCtD
Glipizide—Pruritus—Calcitriol—osteoporosis	0.000442	0.00121	CcSEcCtD
Glipizide—Hyperhidrosis—Zoledronate—osteoporosis	0.000441	0.0012	CcSEcCtD
Glipizide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000441	0.0012	CcSEcCtD
Glipizide—Diarrhoea—Raloxifene—osteoporosis	0.000441	0.0012	CcSEcCtD
Glipizide—Dyspepsia—Pamidronate—osteoporosis	0.00044	0.0012	CcSEcCtD
Glipizide—Dizziness—Estropipate—osteoporosis	0.00044	0.0012	CcSEcCtD
Glipizide—Oedema—Conjugated Estrogens—osteoporosis	0.00044	0.0012	CcSEcCtD
Glipizide—Diarrhoea—Ibandronate—osteoporosis	0.000436	0.00119	CcSEcCtD
Glipizide—Anorexia—Zoledronate—osteoporosis	0.000435	0.00119	CcSEcCtD
Glipizide—Decreased appetite—Pamidronate—osteoporosis	0.000434	0.00119	CcSEcCtD
Glipizide—Dizziness—Alendronate—osteoporosis	0.000433	0.00118	CcSEcCtD
Glipizide—Shock—Conjugated Estrogens—osteoporosis	0.000432	0.00118	CcSEcCtD
Glipizide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000431	0.00118	CcSEcCtD
Glipizide—Erythema—Estradiol—osteoporosis	0.000431	0.00118	CcSEcCtD
Glipizide—Gastrointestinal pain—Risedronate—osteoporosis	0.00043	0.00117	CcSEcCtD
Glipizide—Urticaria—Ethinyl Estradiol—osteoporosis	0.000428	0.00117	CcSEcCtD
Glipizide—Constipation—Pamidronate—osteoporosis	0.000427	0.00117	CcSEcCtD
Glipizide—Pain—Pamidronate—osteoporosis	0.000427	0.00117	CcSEcCtD
Glipizide—Diarrhoea—Calcitriol—osteoporosis	0.000427	0.00117	CcSEcCtD
Glipizide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000426	0.00116	CcSEcCtD
Glipizide—Dizziness—Raloxifene—osteoporosis	0.000426	0.00116	CcSEcCtD
Glipizide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000425	0.00116	CcSEcCtD
Glipizide—Flatulence—Estradiol—osteoporosis	0.000425	0.00116	CcSEcCtD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.000423	0.0068	CbGpPWpGaD
Glipizide—Tension—Estradiol—osteoporosis	0.000423	0.00115	CcSEcCtD
Glipizide—Vomiting—Estropipate—osteoporosis	0.000423	0.00115	CcSEcCtD
Glipizide—Dizziness—Ibandronate—osteoporosis	0.000422	0.00115	CcSEcCtD
Glipizide—Rash—Estropipate—osteoporosis	0.000419	0.00114	CcSEcCtD
Glipizide—Dermatitis—Estropipate—osteoporosis	0.000419	0.00114	CcSEcCtD
Glipizide—Anorexia—Conjugated Estrogens—osteoporosis	0.000419	0.00114	CcSEcCtD
Glipizide—Nervousness—Estradiol—osteoporosis	0.000419	0.00114	CcSEcCtD
Glipizide—Urticaria—Risedronate—osteoporosis	0.000418	0.00114	CcSEcCtD
Glipizide—Headache—Estropipate—osteoporosis	0.000417	0.00114	CcSEcCtD
Glipizide—Vomiting—Alendronate—osteoporosis	0.000417	0.00114	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000416	0.00113	CcSEcCtD
Glipizide—Abdominal pain—Risedronate—osteoporosis	0.000416	0.00113	CcSEcCtD
Glipizide—Muscle spasms—Estradiol—osteoporosis	0.000414	0.00113	CcSEcCtD
Glipizide—Rash—Alendronate—osteoporosis	0.000413	0.00113	CcSEcCtD
Glipizide—Insomnia—Zoledronate—osteoporosis	0.000413	0.00113	CcSEcCtD
Glipizide—Dermatitis—Alendronate—osteoporosis	0.000413	0.00113	CcSEcCtD
Glipizide—Feeling abnormal—Pamidronate—osteoporosis	0.000412	0.00112	CcSEcCtD
Glipizide—Headache—Alendronate—osteoporosis	0.00041	0.00112	CcSEcCtD
Glipizide—Paraesthesia—Zoledronate—osteoporosis	0.00041	0.00112	CcSEcCtD
Glipizide—Vomiting—Raloxifene—osteoporosis	0.00041	0.00112	CcSEcCtD
Glipizide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000409	0.00111	CcSEcCtD
Glipizide—Dyspnoea—Zoledronate—osteoporosis	0.000407	0.00111	CcSEcCtD
Glipizide—Rash—Raloxifene—osteoporosis	0.000406	0.00111	CcSEcCtD
Glipizide—Dermatitis—Raloxifene—osteoporosis	0.000406	0.00111	CcSEcCtD
Glipizide—Somnolence—Zoledronate—osteoporosis	0.000406	0.00111	CcSEcCtD
Glipizide—Vomiting—Ibandronate—osteoporosis	0.000406	0.00111	CcSEcCtD
Glipizide—Tremor—Estradiol—osteoporosis	0.000404	0.0011	CcSEcCtD
Glipizide—Headache—Raloxifene—osteoporosis	0.000404	0.0011	CcSEcCtD
Glipizide—Rash—Ibandronate—osteoporosis	0.000402	0.0011	CcSEcCtD
Glipizide—Dermatitis—Ibandronate—osteoporosis	0.000402	0.0011	CcSEcCtD
Glipizide—Dyspepsia—Zoledronate—osteoporosis	0.000402	0.0011	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.0004	0.00109	CcSEcCtD
Glipizide—Ill-defined disorder—Estradiol—osteoporosis	0.0004	0.00109	CcSEcCtD
Glipizide—Headache—Ibandronate—osteoporosis	0.0004	0.00109	CcSEcCtD
Glipizide—Insomnia—Conjugated Estrogens—osteoporosis	0.000398	0.00108	CcSEcCtD
Glipizide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000397	0.00108	CcSEcCtD
Glipizide—Vomiting—Calcitriol—osteoporosis	0.000397	0.00108	CcSEcCtD
Glipizide—Decreased appetite—Zoledronate—osteoporosis	0.000397	0.00108	CcSEcCtD
Glipizide—Nausea—Estropipate—osteoporosis	0.000395	0.00108	CcSEcCtD
Glipizide—Abdominal pain—Pamidronate—osteoporosis	0.000395	0.00108	CcSEcCtD
Glipizide—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000395	0.00108	CcSEcCtD
Glipizide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000394	0.00108	CcSEcCtD
Glipizide—Rash—Calcitriol—osteoporosis	0.000394	0.00107	CcSEcCtD
Glipizide—Dermatitis—Calcitriol—osteoporosis	0.000393	0.00107	CcSEcCtD
Glipizide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000392	0.00107	CcSEcCtD
Glipizide—Headache—Calcitriol—osteoporosis	0.000391	0.00107	CcSEcCtD
Glipizide—Somnolence—Conjugated Estrogens—osteoporosis	0.000391	0.00107	CcSEcCtD
Glipizide—Pain—Zoledronate—osteoporosis	0.00039	0.00106	CcSEcCtD
Glipizide—Constipation—Zoledronate—osteoporosis	0.00039	0.00106	CcSEcCtD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—IL6—osteoporosis	0.00039	0.00627	CbGpPWpGaD
Glipizide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.00039	0.00626	CbGpPWpGaD
Glipizide—Nausea—Alendronate—osteoporosis	0.000389	0.00106	CcSEcCtD
Glipizide—Malaise—Estradiol—osteoporosis	0.000389	0.00106	CcSEcCtD
Glipizide—Hypersensitivity—Risedronate—osteoporosis	0.000387	0.00106	CcSEcCtD
Glipizide—Vertigo—Estradiol—osteoporosis	0.000387	0.00106	CcSEcCtD
Glipizide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000387	0.00106	CcSEcCtD
Glipizide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000387	0.00106	CcSEcCtD
Glipizide—Syncope—Estradiol—osteoporosis	0.000387	0.00105	CcSEcCtD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—osteoporosis	0.000384	0.00616	CbGpPWpGaD
Glipizide—Nausea—Raloxifene—osteoporosis	0.000383	0.00104	CcSEcCtD
Glipizide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000382	0.00104	CcSEcCtD
Glipizide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000382	0.00104	CcSEcCtD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000381	0.00611	CbGpPWpGaD
Glipizide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00038	0.00104	CcSEcCtD
Glipizide—Nausea—Ibandronate—osteoporosis	0.000379	0.00103	CcSEcCtD
Glipizide—Loss of consciousness—Estradiol—osteoporosis	0.000379	0.00103	CcSEcCtD
Glipizide—Asthenia—Risedronate—osteoporosis	0.000377	0.00103	CcSEcCtD
Glipizide—Feeling abnormal—Zoledronate—osteoporosis	0.000376	0.00103	CcSEcCtD
Glipizide—Constipation—Conjugated Estrogens—osteoporosis	0.000376	0.00103	CcSEcCtD
Glipizide—Pain—Conjugated Estrogens—osteoporosis	0.000376	0.00103	CcSEcCtD
Glipizide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000373	0.00102	CcSEcCtD
Glipizide—Hypertension—Estradiol—osteoporosis	0.000372	0.00102	CcSEcCtD
Glipizide—Pruritus—Risedronate—osteoporosis	0.000372	0.00101	CcSEcCtD
Glipizide—PPARG—Developmental Biology—CAP1—osteoporosis	0.000372	0.00597	CbGpPWpGaD
Glipizide—Nausea—Calcitriol—osteoporosis	0.000371	0.00101	CcSEcCtD
Glipizide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000369	0.00101	CcSEcCtD
Glipizide—Hypersensitivity—Pamidronate—osteoporosis	0.000368	0.001	CcSEcCtD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000367	0.0059	CbGpPWpGaD
Glipizide—Arthralgia—Estradiol—osteoporosis	0.000367	0.001	CcSEcCtD
Glipizide—Myalgia—Estradiol—osteoporosis	0.000367	0.001	CcSEcCtD
Glipizide—Anxiety—Estradiol—osteoporosis	0.000366	0.000998	CcSEcCtD
Glipizide—Urticaria—Zoledronate—osteoporosis	0.000363	0.000989	CcSEcCtD
Glipizide—Discomfort—Estradiol—osteoporosis	0.000363	0.000989	CcSEcCtD
Glipizide—Abdominal pain—Zoledronate—osteoporosis	0.000361	0.000984	CcSEcCtD
Glipizide—Diarrhoea—Risedronate—osteoporosis	0.00036	0.000981	CcSEcCtD
Glipizide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000359	0.000981	CcSEcCtD
Glipizide—Asthenia—Pamidronate—osteoporosis	0.000359	0.000978	CcSEcCtD
Glipizide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000357	0.000973	CcSEcCtD
Glipizide—Confusional state—Estradiol—osteoporosis	0.000355	0.000968	CcSEcCtD
Glipizide—Pruritus—Pamidronate—osteoporosis	0.000354	0.000965	CcSEcCtD
Glipizide—Oedema—Estradiol—osteoporosis	0.000352	0.00096	CcSEcCtD
Glipizide—Urticaria—Conjugated Estrogens—osteoporosis	0.000349	0.000953	CcSEcCtD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000348	0.00559	CbGpPWpGaD
Glipizide—Dizziness—Risedronate—osteoporosis	0.000348	0.000948	CcSEcCtD
Glipizide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000347	0.000948	CcSEcCtD
Glipizide—Shock—Estradiol—osteoporosis	0.000346	0.000944	CcSEcCtD
Glipizide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000343	0.000935	CcSEcCtD
Glipizide—Diarrhoea—Pamidronate—osteoporosis	0.000342	0.000933	CcSEcCtD
Glipizide—Hyperhidrosis—Estradiol—osteoporosis	0.00034	0.000928	CcSEcCtD
Glipizide—Rash—Ethinyl Estradiol—osteoporosis	0.00034	0.000927	CcSEcCtD
Glipizide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00034	0.000927	CcSEcCtD
Glipizide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00034	0.00545	CbGpPWpGaD
Glipizide—Headache—Ethinyl Estradiol—osteoporosis	0.000338	0.000922	CcSEcCtD
Glipizide—Hypersensitivity—Zoledronate—osteoporosis	0.000336	0.000918	CcSEcCtD
Glipizide—Vomiting—Risedronate—osteoporosis	0.000334	0.000912	CcSEcCtD
Glipizide—Rash—Risedronate—osteoporosis	0.000331	0.000904	CcSEcCtD
Glipizide—Dermatitis—Risedronate—osteoporosis	0.000331	0.000903	CcSEcCtD
Glipizide—Dizziness—Pamidronate—osteoporosis	0.00033	0.000902	CcSEcCtD
Glipizide—Headache—Risedronate—osteoporosis	0.000329	0.000898	CcSEcCtD
Glipizide—Asthenia—Zoledronate—osteoporosis	0.000328	0.000893	CcSEcCtD
Glipizide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000324	0.000883	CcSEcCtD
Glipizide—Pruritus—Zoledronate—osteoporosis	0.000323	0.000881	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000321	0.000874	CcSEcCtD
Glipizide—Nausea—Ethinyl Estradiol—osteoporosis	0.00032	0.000874	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.00032	0.00514	CbGpPWpGaD
Glipizide—Insomnia—Estradiol—osteoporosis	0.000318	0.000868	CcSEcCtD
Glipizide—Vomiting—Pamidronate—osteoporosis	0.000318	0.000867	CcSEcCtD
Glipizide—Paraesthesia—Estradiol—osteoporosis	0.000316	0.000862	CcSEcCtD
Glipizide—Asthenia—Conjugated Estrogens—osteoporosis	0.000315	0.00086	CcSEcCtD
Glipizide—Rash—Pamidronate—osteoporosis	0.000315	0.00086	CcSEcCtD
Glipizide—Dermatitis—Pamidronate—osteoporosis	0.000315	0.000859	CcSEcCtD
Glipizide—Dyspnoea—Estradiol—osteoporosis	0.000314	0.000856	CcSEcCtD
Glipizide—Headache—Pamidronate—osteoporosis	0.000313	0.000854	CcSEcCtD
Glipizide—Somnolence—Estradiol—osteoporosis	0.000313	0.000853	CcSEcCtD
Glipizide—Diarrhoea—Zoledronate—osteoporosis	0.000312	0.000852	CcSEcCtD
Glipizide—Nausea—Risedronate—osteoporosis	0.000312	0.000852	CcSEcCtD
Glipizide—Pruritus—Conjugated Estrogens—osteoporosis	0.000311	0.000848	CcSEcCtD
Glipizide—Dyspepsia—Estradiol—osteoporosis	0.00031	0.000845	CcSEcCtD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00031	0.00497	CbGpPWpGaD
Glipizide—Decreased appetite—Estradiol—osteoporosis	0.000306	0.000834	CcSEcCtD
Glipizide—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000306	0.00491	CbGpPWpGaD
Glipizide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000304	0.000829	CcSEcCtD
Glipizide—Dizziness—Zoledronate—osteoporosis	0.000302	0.000824	CcSEcCtD
Glipizide—Constipation—Estradiol—osteoporosis	0.000301	0.000821	CcSEcCtD
Glipizide—Pain—Estradiol—osteoporosis	0.000301	0.000821	CcSEcCtD
Glipizide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000301	0.00082	CcSEcCtD
Glipizide—Nausea—Pamidronate—osteoporosis	0.000297	0.00081	CcSEcCtD
Glipizide—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000292	0.00469	CbGpPWpGaD
Glipizide—Dizziness—Conjugated Estrogens—osteoporosis	0.000291	0.000793	CcSEcCtD
Glipizide—Vomiting—Zoledronate—osteoporosis	0.00029	0.000792	CcSEcCtD
Glipizide—Feeling abnormal—Estradiol—osteoporosis	0.00029	0.000791	CcSEcCtD
Glipizide—Rash—Zoledronate—osteoporosis	0.000288	0.000785	CcSEcCtD
Glipizide—Gastrointestinal pain—Estradiol—osteoporosis	0.000288	0.000785	CcSEcCtD
Glipizide—Dermatitis—Zoledronate—osteoporosis	0.000288	0.000784	CcSEcCtD
Glipizide—Headache—Zoledronate—osteoporosis	0.000286	0.00078	CcSEcCtD
Glipizide—Vomiting—Conjugated Estrogens—osteoporosis	0.000279	0.000762	CcSEcCtD
Glipizide—Urticaria—Estradiol—osteoporosis	0.000279	0.000762	CcSEcCtD
Glipizide—Abdominal pain—Estradiol—osteoporosis	0.000278	0.000759	CcSEcCtD
Glipizide—Rash—Conjugated Estrogens—osteoporosis	0.000277	0.000756	CcSEcCtD
Glipizide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000277	0.000755	CcSEcCtD
Glipizide—Headache—Conjugated Estrogens—osteoporosis	0.000275	0.000751	CcSEcCtD
Glipizide—Nausea—Zoledronate—osteoporosis	0.000271	0.00074	CcSEcCtD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000271	0.00435	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000264	0.00424	CbGpPWpGaD
Glipizide—Nausea—Conjugated Estrogens—osteoporosis	0.000261	0.000712	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—MYC—osteoporosis	0.000261	0.00419	CbGpPWpGaD
Glipizide—Hypersensitivity—Estradiol—osteoporosis	0.000259	0.000707	CcSEcCtD
Glipizide—PPARG—Adipogenesis—IRS2—osteoporosis	0.000258	0.00414	CbGpPWpGaD
Glipizide—Asthenia—Estradiol—osteoporosis	0.000252	0.000689	CcSEcCtD
Glipizide—PPARG—Adipogenesis—LEP—osteoporosis	0.000252	0.00405	CbGpPWpGaD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000251	0.00403	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	0.000251	0.00403	CbGpPWpGaD
Glipizide—Pruritus—Estradiol—osteoporosis	0.000249	0.000679	CcSEcCtD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000247	0.00396	CbGpPWpGaD
Glipizide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000243	0.00391	CbGpPWpGaD
Glipizide—Diarrhoea—Estradiol—osteoporosis	0.000241	0.000657	CcSEcCtD
Glipizide—PPARG—Developmental Biology—TLN1—osteoporosis	0.000233	0.00374	CbGpPWpGaD
Glipizide—Dizziness—Estradiol—osteoporosis	0.000233	0.000635	CcSEcCtD
Glipizide—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000232	0.00373	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—ACTG1—osteoporosis	0.00023	0.00369	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PKM—osteoporosis	0.000228	0.00366	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—FDPS—osteoporosis	0.000228	0.00366	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—IRS1—osteoporosis	0.000225	0.00362	CbGpPWpGaD
Glipizide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000224	0.0036	CbGpPWpGaD
Glipizide—Vomiting—Estradiol—osteoporosis	0.000224	0.00061	CcSEcCtD
Glipizide—ABCC8—Neuronal System—ADCY5—osteoporosis	0.000223	0.00359	CbGpPWpGaD
Glipizide—Rash—Estradiol—osteoporosis	0.000222	0.000605	CcSEcCtD
Glipizide—Dermatitis—Estradiol—osteoporosis	0.000222	0.000605	CcSEcCtD
Glipizide—KCNJ11—Metabolism—PKM—osteoporosis	0.000221	0.00355	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—FDPS—osteoporosis	0.000221	0.00355	CbGpPWpGaD
Glipizide—Headache—Estradiol—osteoporosis	0.00022	0.000601	CcSEcCtD
Glipizide—KCNJ11—Neuronal System—ADCY5—osteoporosis	0.000217	0.00348	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—GPD2—osteoporosis	0.000216	0.00347	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PGLS—osteoporosis	0.000216	0.00347	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000211	0.00339	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—GPD2—osteoporosis	0.00021	0.00337	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PGLS—osteoporosis	0.00021	0.00337	CbGpPWpGaD
Glipizide—Nausea—Estradiol—osteoporosis	0.000209	0.00057	CcSEcCtD
Glipizide—PPARG—Adipogenesis—IGF1—osteoporosis	0.000209	0.00335	CbGpPWpGaD
Glipizide—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000202	0.00325	CbGpPWpGaD
Glipizide—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000201	0.00323	CbGpPWpGaD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.0002	0.00321	CbGpPWpGaD
Glipizide—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000199	0.0032	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PNP—osteoporosis	0.000198	0.00318	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ATIC—osteoporosis	0.000198	0.00318	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ATIC—osteoporosis	0.000192	0.00308	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PNP—osteoporosis	0.000192	0.00308	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—TNF—osteoporosis	0.000192	0.00308	CbGpPWpGaD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—TGFB1—osteoporosis	0.00019	0.00305	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—U2AF1—osteoporosis	0.000182	0.00293	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000179	0.00288	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—WNT1—osteoporosis	0.000179	0.00287	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—LEP—osteoporosis	0.000178	0.00286	CbGpPWpGaD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—osteoporosis	0.000178	0.00285	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CA2—osteoporosis	0.000168	0.0027	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—OXCT1—osteoporosis	0.000168	0.0027	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—MGLL—osteoporosis	0.000164	0.00263	CbGpPWpGaD
Glipizide—PPARG—Metabolism—FDPS—osteoporosis	0.000163	0.00263	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PKM—osteoporosis	0.000163	0.00263	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—OXCT1—osteoporosis	0.000163	0.00262	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CA2—osteoporosis	0.000163	0.00262	CbGpPWpGaD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000163	0.00261	CbGpPWpGaD
Glipizide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000161	0.00258	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—MGLL—osteoporosis	0.000159	0.00255	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PGLS—osteoporosis	0.000155	0.00249	CbGpPWpGaD
Glipizide—PPARG—Metabolism—GPD2—osteoporosis	0.000155	0.00249	CbGpPWpGaD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000148	0.00238	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—ESR2—osteoporosis	0.000145	0.00233	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ATIC—osteoporosis	0.000142	0.00228	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PNP—osteoporosis	0.000142	0.00228	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—IDH2—osteoporosis	0.000139	0.00224	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—RPL24—osteoporosis	0.000135	0.00218	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000135	0.00217	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—IDH2—osteoporosis	0.000135	0.00217	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000133	0.00214	CbGpPWpGaD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000132	0.00212	CbGpPWpGaD
Glipizide—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000131	0.00211	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CYP27A1—osteoporosis	0.000131	0.0021	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000128	0.00206	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ACP5—osteoporosis	0.000127	0.00205	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CYP27A1—osteoporosis	0.000127	0.00204	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—TGFB1—osteoporosis	0.000125	0.00201	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ACP5—osteoporosis	0.000124	0.00198	CbGpPWpGaD
Glipizide—PPARG—Metabolism—OXCT1—osteoporosis	0.000121	0.00194	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CA2—osteoporosis	0.000121	0.00194	CbGpPWpGaD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.00012	0.00193	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.00012	0.00193	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—TPI1—osteoporosis	0.000118	0.0019	CbGpPWpGaD
Glipizide—PPARG—Metabolism—MGLL—osteoporosis	0.000117	0.00189	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—TNF—osteoporosis	0.000117	0.00188	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—VDR—osteoporosis	0.000115	0.00185	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—TPI1—osteoporosis	0.000115	0.00185	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—P4HB—osteoporosis	0.000111	0.00179	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000111	0.00178	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—GAPDH—osteoporosis	0.000109	0.00176	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—P4HB—osteoporosis	0.000108	0.00173	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—RAP1A—osteoporosis	0.000106	0.00171	CbGpPWpGaD
Glipizide—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	0.000106	0.00171	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—GAPDH—osteoporosis	0.000106	0.0017	CbGpPWpGaD
Glipizide—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	0.000105	0.00168	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—RAP1A—osteoporosis	0.000103	0.00166	CbGpPWpGaD
Glipizide—PPARG—Metabolism—IDH2—osteoporosis	9.99e-05	0.0016	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	9.96e-05	0.0016	CbGpPWpGaD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	9.77e-05	0.00157	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	9.71e-05	0.00156	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—IL6—osteoporosis	9.42e-05	0.00151	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CYP27A1—osteoporosis	9.39e-05	0.00151	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ACP5—osteoporosis	9.13e-05	0.00147	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.02e-05	0.00145	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—ESR1—osteoporosis	8.8e-05	0.00141	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—LEP—osteoporosis	8.67e-05	0.00139	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ENO1—osteoporosis	8.61e-05	0.00138	CbGpPWpGaD
Glipizide—PPARG—Metabolism—TPI1—osteoporosis	8.49e-05	0.00136	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PSMA5—osteoporosis	8.48e-05	0.00136	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PSMA2—osteoporosis	8.48e-05	0.00136	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ENO1—osteoporosis	8.35e-05	0.00134	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PSMA2—osteoporosis	8.22e-05	0.00132	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PSMA5—osteoporosis	8.22e-05	0.00132	CbGpPWpGaD
Glipizide—PPARG—Metabolism—P4HB—osteoporosis	7.98e-05	0.00128	CbGpPWpGaD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.92e-05	0.00127	CbGpPWpGaD
Glipizide—PPARG—Metabolism—GAPDH—osteoporosis	7.84e-05	0.00126	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PSMA5—osteoporosis	7.82e-05	0.00126	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PSMA2—osteoporosis	7.82e-05	0.00126	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.76e-05	0.00125	CbGpPWpGaD
Glipizide—PPARG—Metabolism—RAP1A—osteoporosis	7.63e-05	0.00123	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—IL6R—osteoporosis	7.27e-05	0.00117	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	7e-05	0.00112	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—ESR2—osteoporosis	6.98e-05	0.00112	CbGpPWpGaD
Glipizide—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	6.91e-05	0.00111	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CYP19A1—osteoporosis	6.88e-05	0.00111	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CYP19A1—osteoporosis	6.67e-05	0.00107	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.66e-05	0.00107	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—IL6—osteoporosis	6.65e-05	0.00107	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.6e-05	0.00106	CbGpPWpGaD
Glipizide—CYP2C9—Biological oxidations—POMC—osteoporosis	6.38e-05	0.00103	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ENO1—osteoporosis	6.17e-05	0.000991	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PSMA2—osteoporosis	6.08e-05	0.000976	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PSMA5—osteoporosis	6.08e-05	0.000976	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—FDPS—osteoporosis	6.02e-05	0.000967	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PKM—osteoporosis	6.02e-05	0.000967	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PGLS—osteoporosis	5.71e-05	0.000917	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—GPD2—osteoporosis	5.71e-05	0.000917	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ADCY5—osteoporosis	5.62e-05	0.000903	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—GPX1—osteoporosis	5.6e-05	0.0009	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—VDR—osteoporosis	5.54e-05	0.00089	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ADCY5—osteoporosis	5.45e-05	0.000876	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—GPX1—osteoporosis	5.43e-05	0.000873	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PNP—osteoporosis	5.22e-05	0.000838	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ATIC—osteoporosis	5.22e-05	0.000838	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—MTHFR—osteoporosis	5.17e-05	0.000831	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—MTHFR—osteoporosis	5.01e-05	0.000805	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CYP19A1—osteoporosis	4.93e-05	0.000792	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—MYC—osteoporosis	4.58e-05	0.000735	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—OXCT1—osteoporosis	4.44e-05	0.000713	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CA2—osteoporosis	4.44e-05	0.000713	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—MGLL—osteoporosis	4.32e-05	0.000695	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—TGFB1—osteoporosis	4.3e-05	0.00069	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—ESR1—osteoporosis	4.24e-05	0.00068	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—POMC—osteoporosis	4.21e-05	0.000676	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—POMC—osteoporosis	4.14e-05	0.000664	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.08e-05	0.000655	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ADCY5—osteoporosis	4.03e-05	0.000647	CbGpPWpGaD
Glipizide—PPARG—Metabolism—GPX1—osteoporosis	4.02e-05	0.000645	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—TNF—osteoporosis	4.01e-05	0.000645	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—POMC—osteoporosis	4.01e-05	0.000644	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PKM—osteoporosis	3.97e-05	0.000638	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—FDPS—osteoporosis	3.97e-05	0.000638	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PGLS—osteoporosis	3.76e-05	0.000604	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—GPD2—osteoporosis	3.76e-05	0.000604	CbGpPWpGaD
Glipizide—PPARG—Metabolism—MTHFR—osteoporosis	3.71e-05	0.000595	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—IDH2—osteoporosis	3.68e-05	0.000591	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.46e-05	0.000555	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ATIC—osteoporosis	3.44e-05	0.000553	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PNP—osteoporosis	3.44e-05	0.000553	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ACP5—osteoporosis	3.36e-05	0.00054	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.32e-05	0.000533	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—IL6—osteoporosis	3.24e-05	0.00052	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—TPI1—osteoporosis	3.13e-05	0.000502	CbGpPWpGaD
Glipizide—PPARG—Metabolism—POMC—osteoporosis	2.96e-05	0.000476	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—P4HB—osteoporosis	2.94e-05	0.000472	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CA2—osteoporosis	2.93e-05	0.00047	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—OXCT1—osteoporosis	2.93e-05	0.00047	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—GAPDH—osteoporosis	2.89e-05	0.000463	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—MGLL—osteoporosis	2.85e-05	0.000458	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—RAP1A—osteoporosis	2.81e-05	0.000451	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.45e-05	0.000394	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—IDH2—osteoporosis	2.43e-05	0.00039	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.28e-05	0.000366	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ENO1—osteoporosis	2.27e-05	0.000365	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PSMA2—osteoporosis	2.24e-05	0.00036	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PSMA5—osteoporosis	2.24e-05	0.00036	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ACP5—osteoporosis	2.22e-05	0.000356	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—MYC—osteoporosis	2.2e-05	0.000354	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—TPI1—osteoporosis	2.06e-05	0.000331	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—P4HB—osteoporosis	1.94e-05	0.000311	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—GAPDH—osteoporosis	1.9e-05	0.000306	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—RAP1A—osteoporosis	1.85e-05	0.000298	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.82e-05	0.000292	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ENO1—osteoporosis	1.5e-05	0.000241	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ADCY5—osteoporosis	1.48e-05	0.000238	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—GPX1—osteoporosis	1.48e-05	0.000238	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PSMA2—osteoporosis	1.48e-05	0.000237	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PSMA5—osteoporosis	1.48e-05	0.000237	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—MTHFR—osteoporosis	1.36e-05	0.000219	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.2e-05	0.000192	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—POMC—osteoporosis	1.09e-05	0.000175	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ADCY5—osteoporosis	9.79e-06	0.000157	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—GPX1—osteoporosis	9.75e-06	0.000157	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—MTHFR—osteoporosis	9e-06	0.000145	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—POMC—osteoporosis	7.2e-06	0.000116	CbGpPWpGaD
